SCPH
Company Description
scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.
Track Record
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.33M | 13.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (85.15M) | (54.81M) | (36.84M) | (28.03M) | (32.21M) | (34.41M) | (29.44M) | (23.82M) | (24.38M) | (10.52M) |
| EPS | -1.91 | -1.42 | -1.30 | -1.02 | -1.31 | -1.85 | -1.59 | -8.04 | -2.18 | -0.94 |
| Free Cash Flow | (70.56M) | (59.28M) | (34.60M) | (27.16M) | (27.69M) | (30.44M) | (28.81M) | (22.88M) | (15.46M) | (9.66M) |
| FCF / Share | -1.58 | -1.54 | -1.22 | -0.99 | -1.13 | -1.64 | -1.55 | -7.72 | -1.38 | -0.86 |
| Operating CF | (70.54M) | (59.24M) | (34.58M) | (27.15M) | (27.69M) | (30.44M) | (28.81M) | (22.68M) | (15.46M) | (9.64M) |
| Total Assets | 107.52M | 94.48M | 124.19M | 79.04M | 109.05M | 77.28M | 93.75M | 122.05M | 39.77M | 1.85M |
| Total Debt | 52.69M | 40.27M | 37.37M | 17.64M | 20.21M | 20.27M | 11.34M | 11.34M | 0 | 0 |
| Cash & Equiv | 75.66M | 46.81M | 71.06M | 74.27M | 71.82M | 72.81M | 89.66M | 118.30M | 39.28M | 1.57M |
| Book Value | 13.32M | 37.22M | 72.43M | 56.47M | 82.17M | 51.37M | 78.74M | 106.00M | (37.07M) | (18.24M) |
| Return on Equity | -6.39 | -1.47 | -0.51 | -0.50 | -0.39 | -0.67 | -0.37 | -0.22 | N/A | N/A |
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.04M | 11.75M | 12.15M | 10.03M | 8.05M | 6.10M | 6.10M | 3.80M | 1.64M | 2.06M | 0 | 0 |
| Net Income | (18.02M) | (19.74M) | (18.84M) | (35.10M) | (17.09M) | (14.11M) | (13.81M) | (15.63M) | (14.15M) | (12.83M) | (9.76M) | (10.33M) |
| EPS | -0.34 | -0.37 | -0.42 | -0.75 | -0.44 | -0.36 | -0.36 | -0.40 | -0.37 | -0.34 | -0.31 | -0.38 |
| Free Cash Flow | (16.11M) | (17.14M) | (15.20M) | (17.43M) | (20.23M) | (17.70M) | (15.20M) | (13.45M) | (14.14M) | (16.49M) | (11.84M) | (8.21M) |
| FCF / Share | -0.30 | -0.32 | -0.34 | -0.37 | -0.52 | -0.45 | -0.39 | -0.35 | -0.37 | -0.44 | -0.38 | -0.30 |
| Operating CF | (16.11M) | (17.14M) | (15.19M) | (17.42M) | (20.23M) | (17.70M) | (15.16M) | (13.45M) | (14.14M) | (16.49M) | (11.84M) | (8.20M) |
| Total Assets | 80.25M | 90.96M | 107.52M | 125.07M | 65.46M | 78.45M | 94.48M | 106.10M | 114.17M | 127.37M | 124.19M | 48.40M |
| Total Debt | 52.45M | 52.36M | 52.69M | 52.50M | 41.36M | 40.80M | 40.27M | 39.81M | 38.01M | 37.68M | 37.37M | 11.18M |
| Cash & Equiv | 40.81M | 57.54M | 75.66M | 91.48M | 38.50M | 58.45M | 46.81M | 35.04M | 71.35M | 75.45M | 71.06M | 41.29M |
| Book Value | (21.32M) | (5.13M) | 13.32M | 30.71M | 9.25M | 24.57M | 37.22M | 49.15M | (251.90M) | (237.75M) | (226.54M) | 31.11M |
| Return on Equity | N/A | N/A | -1.41 | -1.14 | -1.85 | -0.57 | -0.37 | -0.32 | N/A | N/A | N/A | -0.33 |